摘要
目的探讨人重组促红细胞生成素联合布地奈德对支气管肺发育不良早产儿炎性因子及肺功能改善的影响。方法选择2021年11月至2022年10月收治116例支气管肺发育不良早产儿,随机数字表法为对照组和观察组,每组58例,对照组给予布地奈德治疗,观察组在此基础上再给予人重组促红细胞生成素治疗,比较治疗前后2组炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)]情况;比较治疗前后2组肺功能[吸频率(RR)、吸气峰压(PIP)、潮气量(VT)]情况;比较治疗前后2组血气指标[氧分压(PO_(2))、氧饱和度(SpO_(2))及二氧化碳分压(PCO_(2))]变化情况;观察2组疗效况及并发症情况。结果治疗前,2组血清TNF-α、IL-6、IL-8水平比较,差异无统计学意义(P>0.05);治疗后,2组血清TNF-α、IL-6、IL-8水平降低,观察组更明显(P<0.05);治疗前,2组RR、PIP、VT比较差异无统计学意义(P>0.05);治疗后,2组RR、PIP、VT指标明显改善,观察组更明显(P<0.05);治疗前,2组PO_(2)、SpO_(2)、PCO_(2)比较,差异无统计学意义(P>0.05);治疗后,2组PO_(2)、SpO_(2)、PCO_(2)指标明显改善,观察组更明显(P<0.05);观察组疗效优于对照组,并发症发生率低于对照组(P<0.05)。结论对支气管肺发育不良早产儿给予人重组促红细胞生成素联合布地奈德治疗,可改善其气血指标,减低炎症水平,改善肺功能。
Objective To investigate the effect of recombinant human erythropoietin combined with budesonide on inflammatory factors and pulmonary function improvement in premature infants with bronchopulmonary dysplasia.Methods A total of 116 premature infants with bronchopulmonary dysplasia admitted to our hospital from November 2021 to OctobeR2022 were randomly divided into the control group(58 cases)and the observation group(58 cases).Patients in the control group were treated with budesonide,and those in the observation group were treated with recombinant human erythropoietin combined with budesonide.Inflammatory factors before and after treatment were compared,including the tumor necrosis factor alpha(TNF-α),interleukin 6(IL-6)and IL-8.Pulmonary function before and after treatment were compared,including the respiratory rate(RR),peak inspiratory pressure(PIP)and tidal volume(VT).Blood gas indexes before and after treatment were compared,including the partial pressure of oxygen(PO_(2)),oxygen saturation(SpO_(2))and partial pressure of carbon dioxide(PCO_(2)).The curative effect and complications of the two groups were compared.Results Before treatment,there were no significant differences in the serum TNF-α,IL-6 and IL-8 levels between groups(P>0.05),which were significantly reduced in the both groups after treatment and the decreases were more pronounced in the observation group than those of the control group(P<0.05).Before treatment,there were no significant differences in the RR,RIP and VT between groups(P>0.05),which were significantly improved in the both groups after treatment and the improvements were more pronounced in the observation group than those of the control group(P<0.05).Before treatment,there were no significant differences in the PO_(2),SpO_(2) and PCO_(2) between groups(P>0.05),which were significantly improved in the both groups after treatment and the improvements were more pronounced in the observation group than those of the control group(P<0.05).The efficacy of the observation group was significantly betteRthan that of the control group,and the incidence of complications was significantly lower (P<0.05).Conclusion The treatment of human recombinant erythropoietin combined with budesonide in premature infants with bronchopulmonary dysplasia can improve their blood gas indexes,reduce the level of inflammation and improve pulmonary function.
作者
王晓娇
闫雪峰
冶斐然
WANG Xiaojiao;YAN Xuefeng;YE Feiran(Department of Neonatology,Zhangjiakou Maternal and Child Health Hospital,Heibei,Zhangjiakou 075000,China)
出处
《河北医药》
CAS
2024年第2期235-238,共4页
Hebei Medical Journal
基金
河北省医学科学研究课题(编号:20232078)。
关键词
人重组促红细胞生成素
布地奈德
支气管肺发育不良早产儿
炎症因子
肺功能
recombinant human erythropoietin
budesonide
premature infants with bronchopulmonary dysplasia
inflammatory factors
pulmonary function
